Drug
Fulvestrant clinical trials
Also written Faslodex, ZD9238 and ICI 182,780.
- studies test it
- 236
- open now
- 47
- in phase 3
- 34
- first study started
- 1997
Keep track of what changes. Save the Fulvestrant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
236 studies that test it; most in 2017 (21)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 15 |
| 2005 | 5 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 8 |
| 2015 | 10 |
| 2016 | 13 |
| 2017 | 21 |
| 2018 | 14 |
| 2019 | 9 |
| 2020 | 12 |
| 2021 | 17 |
| 2022 | 19 |
| 2023 | 14 |
| 2024 | 8 |
| 2025 | 12 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 65
- Phase 2
- 153
- Phase 3
- 34
- Phase 4
- 8
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 94 · Other 142
AstraZeneca (29) · Novartis Pharmaceuticals (9) · Fudan University (9) · National Cancer Institute (NCI) (6) · Eli Lilly and Company (5) · ImmunityBio, Inc. (5) · Memorial Sloan Kettering Cancer Center (4) · M.D. Anderson Cancer Center (4)
Often tested with
Tested in the same studies.
Palbociclib (30) · Anastrozole (23) · Abemaciclib (18) · Letrozole (17) · Exemestane (14) · Paclitaxel (13) · Ribociclib (12) · Bevacizumab (12)
Studies
Open first, then newest update. How each study uses Fulvestrant is read from its arms, and is right about nine times in ten.
Testing it · 236
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07892274Written as Fulvestrant
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208Written as Fulvestrant
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07857226Written as Fulvestrant
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584Written as Fulvestrant
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Fulvestrant
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Ensem TherapeuticsNCT06993844Written as ETX-636 dose escalation in combination with fulvestrant
- A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerNot yet recruitingPhase 1Genentech, Inc.NCT07867262Written as Fulvestrant
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Written as Arm A: Gedatolisib + Palbociclib + Fulvestrant
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Fulvestrant
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596Written as Fulvestrant
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07368998Written as Fulvestrant
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Written as Fulvestrant
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Fulvestrant
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingPhase 1/2Novartis PharmaceuticalsNCT06726148Written as fulvestrant
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786Written as Fulvestrant
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsRecruitingPhase 1IDEAYA BiosciencesNCT07540572Written as Fulvestrant injection
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390Written as Inavolisib + Ribociclib + Fulvestrant
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingPhase 2MedSIRNCT07619066Written as Fulvestrant
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Written as Fulvestrant
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingPhase 1/2Adrienne G. WaksNCT05608252Written as Fulvestrant
See all 236 studies that test Fulvestrant →
Given in every arm · 181 — Fulvestrant is usual care beside what is tested
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Written as Fulvestrant
- Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingPhase 2PfizerNCT04606446Written as Fulvestrant
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 1/2PfizerNCT04557449Written as Fulvestrant
- Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerRecruitingPhase 1Novartis PharmaceuticalsNCT07604571Written as Fulvestrant
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingPhase 3PfizerNCT07062965Written as Fulvestrant
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsRecruitingPhase 1BeOne MedicinesNCT06120283Written as Fulvestrant
- Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsRecruitingPhase 1/2Novartis PharmaceuticalsNCT07288359Written as Fulvestrant
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336Written as Fulvestrant
- A Phase 1/2a Study of K-1728 in Advanced Solid TumorsNot yet recruitingPhase 1/2KymaThera, Inc.NCT07861932Written as Fulvestrant
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingPhase 1Bristol-Myers SquibbNCT06997029Written as Fulvestrant
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07405801Written as Fulvestrant
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsRecruitingPhase 1Olema Pharmaceuticals, Inc.NCT06784193Written as Fulvestrant
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRecruitingPhase 3Relay Therapeutics, Inc.NCT06982521Written as Fulvestrant
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingPhase 1TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06625775Written as Fulvestrant
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Written as Fulvestrant
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Written as Fulvestrant
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsRecruitingPhase 1BeOne MedicinesNCT07226349Written as Fulvestrant
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303Written as Fulvestrant
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269Written as Fulvestrant
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsRecruitingPhase 1/2Terremoto Biosciences Inc.NCT07109726Written as Fulvestrant injection
Showing 20 of 181.
As the comparator · 21 — what is tested is compared with Fulvestrant
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173Written as Fulvestrant injection
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.RecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07354022Written as Fulvestrant injection ;Dalpiciclib Isethionate
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05472792Written as tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerRecruitingPhase 3InventisBio Co., LtdNCT06954961Written as Fulvestrant
- A Study of Single Dose of BL0175 in Postmenopausal WomenNot yet recruitingPhase 1Shanghai Best-Link Bioscience, LLCNCT07366632Written as Fulvestrant
- Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorRecruitingPhase 2National University Hospital, SingaporeNCT05181033Written as Fulvestrant
- A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerNot yet recruitingPhase 2Li HuipingNCT06339281Written as apatinib mesylate+Fulvestrant injection
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Written as Fulvestrant
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingPhase 2PfizerNCT05226871Written as Fulvestrant
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingPhase 2AstraZenecaNCT04214288Written as Fulvestrant
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingPhase 3Olema Pharmaceuticals, Inc.NCT06016738Written as Fulvestrant
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06680921Written as Fulvestrant injection
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as Fulvestrant
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingPhase 3PfizerNCT05654623Written as Fulvestrant
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerTerminatedPhase 2SanofiNCT04059484Written as Fulvestrant
- Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationCompletedPhase 2Sermonix Pharmaceuticals Inc.NCT03781063Written as Fulvestrant
- A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast CancerCompletedPhase 2Lund University HospitalNCT02958852Written as Fulvestrant
- A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) TherapyTerminatedPhase 2Genentech, Inc.NCT02569801Written as Fulvestrant
- Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.CompletedPhase 1AstraZenecaNCT03236974Written as Standard Arm - Fulvestrant
- A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast CancerStatus unknownPhase 2Instituto Nacional de Cancer, BrazilNCT03024580Written as Fulvestrant 50Mg Solution for Injection
Showing 20 of 21.
Codes
What other systems call Fulvestrant · ClinicalTrials.gg INT006680
- MeSH (NLM) D000077267FulvestrantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 22X328QOC4FULVESTRANTConfirmed FDA, NLM, Wikidata
- RxNorm 282357Confirmed FDA, Wikidata
- Wikidata Q5508491fulvestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1379FulvestrantOne source FDA
- DrugBank DB00947One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077267 | Fulvestrant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 22X328QOC4 | FULVESTRANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 282357 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5508491 | fulvestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1379 | Fulvestrant | One source FDA |
| DrugBank | DB00947 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.